Furthermore, among EGFR TKI‐treated lung cancers, there is little clinical data available on the use of weak (tramadol, codeine, buprenorphine) or strong (morphine, oxycodone, fentanyl, hydromorphone) opioids and their effect on treatment outcomes. This evidence concerns the gene EGFR and lung carcinoma.